Bruna Cuccurazzu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bruna Cuccurazzu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Adam K. Klein
Behavioral Pharmacology Laboratory, Department of Psychological and Brain Sciences, University of California, Santa Barbara, CA, 93106-9660, USA
1 shared publication Adam L. Halberstadt
1 shared publication- Adam L. Halberstadt
Department of Psychiatry, University of California San Diego, La Jolla, USA
1 shared publication Albert Lin
1 shared publicationAlexander M. Sherwood
Usona Institute, Madison, USA
1 shared publicationAndrew B. Cao
Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, USA
1 shared publication
Latest Publications
- 7 August 2026
- Published by Elsevier in The Journal of Pain
- Vol. 50
Feasibility and tolerability of psilocybin for phantom limb pain
- 7 August 2026
- Published by Elsevier in The Journal of Pain
- Vol. 50
Feasibility and tolerability of psilocybin for phantom limb pain
- Top Cited PapersOpen Access
- 15 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential
Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT2A-Gq/11 and β-arrestin2 transducers, making their respective roles unclear. To elucidate this, we develop a series of 5-HT2A-selective ligands with varying Gq efficacies, including β-arrestin-biased ligands. We show that 5-HT2A-Gq but not 5-HT2A-β-arrestin2 recruitment efficacy predicts psychedelic potential, assessed using head-twitch response (HTR) magnitude in male mice. We further show that disrupting Gq-PLC signaling attenuates the HTR and a threshold level of Gq activation is required to induce psychedelic-like effects, consistent with the fact that certain 5-HT2A partial agonists (e.g., lisuride) are non-psychedelic. Understanding the role of 5-HT2A Gq-efficacy in psychedelic-like psychopharmacology permits rational development of non-psychedelic 5-HT2A agonists. We also demonstrate that β-arrestin-biased 5-HT2A receptor agonists block psychedelic effects and induce receptor downregulation and tachyphylaxis. Overall, 5-HT2A receptor Gq-signaling can be fine-tuned to generate ligands distinct from classical psychedelics.
- 15 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Top Cited PapersOpen AccessIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT2A-Gq/11 and β-arrestin2 transducers, making their respective roles unclear. To elucidate this, we develop a series of 5-HT2A-selective ligands with varying Gq efficacies, including β-arrestin-biased ligands. We show that 5-HT2A-Gq but not 5-HT2A-β-arrestin2 recruitment efficacy predicts psychedelic potential, assessed using head-twitch response (HTR) magnitude in male mice. We further show that disrupting Gq-PLC signaling attenuates the HTR and a threshold level of Gq activation is required to induce psychedelic-like effects, consistent with the fact that certain 5-HT2A partial agonists (e.g., lisuride) are non-psychedelic. Understanding the role of 5-HT2A Gq-efficacy in psychedelic-like psychopharmacology permits rational development of non-psychedelic 5-HT2A agonists. We also demonstrate that β-arrestin-biased 5-HT2A receptor agonists block psychedelic effects and induce receptor downregulation and tachyphylaxis. Overall, 5-HT2A receptor Gq-signaling can be fine-tuned to generate ligands distinct from classical psychedelics.